ArticleEuropean radiology2026
User validation of an AI-assisted ultrasound guidance system for rapid vascular access.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesVascular cannulation enables life-saving resuscitation in traumatic hemorrhage. The AI-GUIDE-LL is a handheld ultrasound-guided robotic device enabling inexperienced medical providers to obtain femoral vascular access. Device efficacy has been demonstrated in expert-operated porcine models, though performance among inexperienced operators and in humans is unknown. We evaluated the AI-GUIDE-LL's performance among novice clinicians to target human femoral vessels and accurately deploy needles in phantoms. MATERIALS AND
methodsThis single-site prospective study recruited medical professionals without ultrasound-guided procedural experience. Users attempted femoral artery needle insertion in five human CT-derived inguinal phantoms using fluid aspiration as the reference standard, with three needle insertions permitted per phantom. Subsequently, they used the device to target healthy human volunteer femoral vessels, assessing target vessel localization and common femoral segment identification. Success was defined by expert review of ultrasound images and video recordings.
resultsThirty clinicians (seven advanced practice providers, five EMTs, nine physicians, and nine registered nurses) achieved correct needle insertion in phantoms in 93% (140/150) of trials, with a median completion time of 44 s and a mean of 1.1 attempts. 28 volunteers were scanned by 28 clinicians. Clinicians successfully targeted 97% (93/96) of vessels with a median time of 25 s. Common femoral segment confirmation was achieved in only 20% of trials.
conclusionThe AI-GUIDE-LL enables rapid, accurate femoral vessel localization and needle insertion among novice clinicians, supporting feasibility for field-forward military and point-of-care civilian settings. Reliable segment-specific localization above the femoral bifurcation, necessary for large-bore arterial procedures, remains an important limitation requiring further work. KEY POINTS: Question AI-GUIDE-LL is a handheld robotic system that integrates artificial intelligence and ultrasound guidance to assist non-expert users in performing femoral vascular access for rapid point-of-care interventions. Findings Clinicians with limited ultrasound experience successfully localized femoral vessels, achieving 93% phantom needle insertion success and 97% target vessel localization in human trials. Clinical relevance AI-GUIDE-LL may enable clinicians with limited ultrasound training to perform timely femoral cannulation for life-saving interventions, including fluid resuscitation in traumatic hemorrhage, particularly in military or resource-limited environments.
Indexed as
Identifiers
42728383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.